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1. Introduction
Sudden cardiac death (SCD) remains a major public health issue with an estimated annual inci‐
dence of 300,000 cases per year. The ACC/AHA/ESC 2006 guidelines define SCD as “death from
an unexpected circulatory arrest, usually due to a cardiac arrhythmia occurring within an hour
of the onset of symptoms” [1]. Trials on traditional antiarrhythmic drugs have failed to show
any mortality benefit even when compared to placebo or implantable cardiovertor defibrilla‐
tors (ICDs) [2]. Most of the patients experiencing sudden cardiac arrest have left ventricular
ejection fraction (LVEF) > 50%, with the majority of these patients having a history of coronary
artery disease (CAD). Majority of Sudden Cardiac Arrests (85-90%) are the first arrhythmic
event a patient experiences[3].Beta blocker therapy, Angiotensin enzymes inhibitors (ACE-I) as
well as aldosterone antagonists have been shown to decrease the risk of sudden cardiac death
especially in post myocardial infarction (MI) patients and in patients with congestive heart fail‐
ure. This chapter will review the data on the effects of traditional heart failure medications, es‐
pecially beta blockers, Renin Angiotensin system blockers, as well as Statin therapy on sudden
cardiac death in post MI patients and in patients with cardiomyopathy.
2. β-blockers and sudden cardiac death prevention
2.1. Potential mechanisms of β-blockers on sudden cardiac death prevention
Multiple studies have suggested that the major mechanisms responsible for the cardiac
arrhythmias associated with sudden cardiac death are ventricular tachycardia (VT) and
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ventricular fibrillation (VF). For these arrhythmias to occur, an interaction between substrate
(ventricular enlargement and/or hypertrophy, myocardial scar due to ischemic or non-
ischemic injury) and triggers (electrolyte abnormalities, changes in the sympathetic and
parasympathetic activity, neuro-humeral factors, and premature ventricular contractions) is
necessary to initiate reentry leading to ventricular tachycardia and ventricular fibrillation
(Figure 1).
Many anatomic or functional substrates such as coronary artery disease, cardiomyopathy or
primary electrophysiological disease can lead to sudden cardiac death. Progression of these
disease states leads to sympathetic activation. At the cellular level, sympathetic and vagal
denervation caused by myocardial ischemia leads to an increase in interstitial potassium and
intracellular calcium concentrations [3]. This results in slowed conduction and induces
spontaneous electrical activity. All these factors contribute to reentry; which is the most
common mechanism of ventricular tachycardia in patients with ischemic heart disease [4].
As myocardial ischemia progresses the neurohumoral system exerts further stimulation of the
sympathetic system and the renin-angiotensin-aldosterone system (RAAS). This neurohu‐
moral cascade leads to increasing levels of norepinephrine, angiotensin II, aldosterone,
endothelin and vasopressin. Increased norepinephrine levels lead to increased preload and
after-load, which in turn increases myocardial oxygen demand. Furthermore, the activation
of these systems promotes fibrosis and necrosis [5-7], which over time will lead to cardiac
remodeling, left ventricular dilatation, fibrosis and progression into heart failure [8].
Three types of β-receptors are known, designated β1, β2 and β3 receptors. β1 receptors are
located mainly in the heart and in the kidneys and are down regulated in heart failure due to
chronically elevated norepinephrine levels. β2 receptors are located mainly in the lungs,
gastrointestinal tract, liver, uterus, vascular smooth muscle, and skeletal muscle. β3 receptors
are located in fat cells. β1and β2receptors activate cyclic adenosine mono-phosphate (cAMP),
which acts as a second messenger and leads to increased contractility (inotropy), increased
heart rate (which increases myocardial oxygen demand), increased conduction velocity (which
may promote reentry) and have a positive lusitropic effect, which improves active relaxation
[9]. β2receptors promote the release of renin, which in turn activates angiotensin II and
aldosterone, both of which elevate the blood pressure, increase after-load, promote potassium
wasting and activate fibroblasts leading to fibrosis.
β-blockers exert their protective effect on the heart via different mechanisms. β-blockers reduce
ischemia by decreasing the heart rate, which is the major determinant of myocardial oxygen
demand[10]. At the cellular level, β-blockers decrease electrical excitability by limiting calcium
entry via catecholamine-dependent channels [9]. All this helps decrease left ventricular mass
and volume, decrease LV end diastolic pressure and improve LV function [11]. β-blockers are
also considered a class II antiarrhythmic medications. They decrease spontaneous depolari‐
zation, prolong the sinus node cycle length, atrioventricular conduction times and atrioven‐
tricular refractory periods. They also increase the excitable gap, which prevents reentry and
increases the success of anti-tachycardia pacing [12].
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Figure 1. Venn diagram showing interaction of various anatomic/functional and transient factors that modulate po‐
tential arrhythmogenic mechanisms capable of causing sudden cardiac death (From Douglas P. Zipes and Hein J. J.
Wellens “Sudden Cardiac Death” Circulation. 1998; 98:2334-2351, With Permission)
2.2. Effect of β-blockers on sudden cardiac death prevention in post myocardial infarction
patients
β-blockers therapy has been studied in the post myocardial infarction (MI) patients since 1965
when propranolol was found to reduce mortality after acute MI[13]. Pivotal trials such as the
Norwegian Multicenter Study Group (utilizing Timolol at a starting dose of 5 mgs/day with target
of 20 mgs/day), β-blocker Heart Attack Trial (BHAT, utilizing propranolol at a dose of 180 to 240
mgs/day) in the 1980s showed reduction in total mortality and sudden cardiac death [14, 15].
As therapies post- MI evolved and ACE-I inhibitors were introduced several other trials,
including the Survival and Ventricular Enlargement (SAVE) and Acute Infarction Ramipril Efficacy
(AIRE) trials demonstrated that β-blockers provided additional reduction in cardiovascular
mortality independent of the use of ACE-I inhibitors[16, 17].
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A meta-analysis evaluated several randomized clinical trials looking at the benefits of β-
blockers treatment post MI. This analysis revealed a significant reduction in mortality with β-
blocker therapy (HR= 0.77, 95% confidence interval: 0.69 to 0.85)[18]. Secondary to lack of
physician prescription of β-blocker therapy despite evidence of its benefit the Cooperative
Cardiovascular Project was undertaken. This was an observational report that evaluated the
care of 200,000 Medicare patients with the diagnosis of MI. Only 34% of the patients were given
β-blockers. The mortality reduction for patients who were prescribed beta- blockers at the time
of discharge from the hospital was 40% [19].
A sub-analysis  of  BHAT  trial  showed that  propranolol  decreased mortality  and sudden
cardiac death in the subset of patients with depressed LVEF [20]. But it was not until the
Carvedilol  Post-Infarct  Survival  Control  in  Left  Ventricular  Dysfunction  trial  (CAPRICORN)
was a  focus  also  placed on AMI patient  with  left  ventricular  (LV)  dysfunction.  CAPRI‐
CORN  was a multinational  prospective,  randomized trial  recruiting patients  with recent
acute  MI  (3-21  days)  and left  ventricular  (LV)  dysfunction  with  ejection  fraction  (EF)  ≤
40%. A total  of  984 patients  were placed on placebo and 975 patients were allocated to
Carvedilol  therapy post  MI  with  an average  follow up of  1.3  years.  The initial  starting
dose was 6.25 mgs orally twice daily with target dose of 25 mgs orally twice daily. All-
cause mortality was lower in the carvedilol group than in the placebo group (Hazard Ra‐
tio  of  0.77,  95%  CI  of  0.60—0.98,  p=0.03)  [21].  Several  secondary  prevention  trials  had
demonstrated significant reductions in ventricular arrhythmias but it was not until CAP‐
RICORN  that  patients  with  substantial  left  ventricular  dysfunction  also  demonstrated  a
significant  reduction  in  malignant  ventricular  arrhythmias  (HR  of  0.37  (95%  CI  0.24  to
0.58;  p  <  0.0001)[22].  It  is  important  to  emphasise  that  in  this  trial  that  98% of  the  pa‐
tients  were treated with an ACE-I inhibitor.  The effect  of  ACE-I inhibitors on reduction
of ventricular arrhythmias will be discussed in a later section.
2.3. Effect of β-blockers on sudden cardiac death prevention in patients with congestive
heart failure
β-blockers were initially thought to be contra-indicated in patients with heart failure due to
their negative inotropic effects in the short term. However, later studies showed they consis‐
tently improve morbidity and mortality in patients with heart failure; they also lead to a 40%
reduction in hospitalization. Currently, there are 3 medications available in the United States
that have shown mortality benefits in patients with heart failure. Carvedilol is a non-selective
β1, β2and α1 blocker that was tested in two trials and was shown to improve mortality. The
first is the US Carvedilol trial which enrolled 1094 patients with congestive heart failure (CHF)
and left ventricular ejection fraction (LVEF) of ≤ 35%. Patients were assigned to four treatment
protocols based on exercise capacity. Within each protocol patients were assigned to either
placebo (n=398) or Carvedilol (n=696). Although this trial was not designed as mortality trial,
itdemonstrated a 65% decrease in the risk of death with Carvedilol compared to placebo
(p<0.001). Sudden death was reduced from 3.8% in the placebo group to 1.7% in the Carvedilol
group [23].
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The  Carvedilol  Prospective  Randomized  Cumulative  Survival  (COPERNICUS)  trial  examined
the effect of Carvedilol in 2289 patients with severe CHF, defined as dyspnea at rest and
LVEF ≤ 25%. This trial  validated the mortality benefit  of  Carvedilol  in patients with se‐
vere  heart  failure  with  a  50%  reduction  in  all-cause  mortality  (HR  0.50,  95%  CI  of
0.10-0.63) [24]. Unfortunately this trial did not have data available on the impact of Car‐
vedilol on sudden death.
The Cardiac Insufficiency Bisoprolol Study (CIBIS) II was a multicenter, double-blind, random‐
ized, placebo-controlled trial that evaluated the efficacy of Bisoprolol in reducing the incidence
of all-cause mortality in heart failure. Bisoprolol is a β1receptor blocker, and the target dose
was 10 mgs daily. All patients enrolled received standard therapy with diuretics and ACE-I
inhibitors. A total of2647 patients with New York Heart Association (NYHA) class III or IV
with LVEF of ≤ 35% were randomized to either Bisoprolol (n=1327) or placebo (n=1320). This
study was stopped prematurely because Bisoprolol showed a significant mortality benefit.
Death from any cause in the Bisoprolol group was 11.8% versus 17.3% in the placebo group
(HR, 0.66, 95% CI, 0.54-0.80). Sudden death was also reduced in the Bisoprolol group by 42%
compared to the placebo group [25].
The Metoprolol CR/XL Randomized Intervention Trial in CHF (MERIT-HF) was a double-blind
randomized controlled study which included 3991 patients with CHF, NYHA class II-IV with
an LVEF of ≤40%. These patients were stable on optimal medical therapy. This trial evaluated
whether controlled release/extended release formulation of Metoprolol taken daily would
reduce mortality in this patient population. The starting dose was 12.5 mgs once daily with
target dose of 200 mgs orally once daily. Patients were randomized to Metoprolol CR/XL
(n=1990) up-titrated to 200 mg daily over and eight week period of time or placebo (n=2001).
The trial demonstrated a 34% relative risk reduction in all-cause mortality with controlled
release/extended release formulation of Metoprolol. Similar, to CIBIS II, MERIT–HF showed
a 41% relative risk reduction of sudden death [26].
2.4. Effect of β-blockers on sudden cardiac death prevention in patients who survived a
cardiac arrest
In patients who have implantable cardioverter defibrillators (ICDs), β-blockers have been
shown to decrease the frequency of ICD shocks [27]. In an analysis of the Antiarrhythmics
Versus Implantable Defibrillators Registry (AVID registry), β-blockers therapy was associated
with lower mortality in patients with sustained ventricular tachycardia [28]. β-Blockers
increase the time to first ICD shock in patients implanted for secondary prevention of sudden
death[29].
Furthermore, the higher the dose of β-blockers used, the less patients experience VT and the
more likely the therapies are successful. In a study of 282 patients with left ventricular
dysfunction (EF < 50%) with standard indications for ICD without cardiac resynchronization
therapy, the higher the dose of β-blockers
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3. Renin-Angiotensin-aldosterone system and sudden cardiac death
prevention
3.1. Potential mechanisms of Renin-Angiotensin-aldosterone system inhibitors/blockers on
sudden cardiac death prevention
The  Renin-Angiotensin-aldosterone  system  (RAAS)  is  activated  during  many  disease
states,  but  especially  during  myocardial  ischemia  and  heart  failure.  Renin  activates  the
angiotensin converting enzyme, which converts Angtiotensin I  to Angiotensin II.  Angio‐
tensin II  is  a potent vasoconstrictor;  it  activates fibroblasts promoting interstitial  fibrosis
and scar formation. Furthermore,  Angiotensin II  also activates the secretion of Aldoster‐
one  and  Norepinephrine.  All  of  these  factors  also  increase  after-load,  which  increases
myocardial  oxygen  demand.  At  the  cellular  level,  angiotensin  II  decreases  the  effective
refractory period of  the cardiac myocyte and enhances conduction [30].Furthermore,  Al‐
dosterone promotes sodium retention, increases potassium secretion in the urine and ac‐
tivates fibroblasts leading to myocardial and vascular fibrosis. This promotes remodeling,
LV  dilatation  and  creates  the  substrate  for  reentry  [31].  ACE-I  inhibitors  decrease  pre-
load  and  after-load,  which  decreases  myocardial  oxygen  demand and LV end diastolic
pressure. They also block Angiotensin II production and inhibit the breakdown of brady‐
kinin [23]. Blocking angiotensin II prevents the progression of ventricular remodeling, re‐
duces  ventricular  dilatation  and  fibrosis.  ACE-I  inhibitors  result  in  a  reduction  in
potassium depletion and have several  effects  on the  autonomic  nervous  system via  en‐
hanced baroreflex sensitivity and hemodynamics which can lead to reduced sympathetic
and  parasympathetic  tone  and  circulating  catecholamines.  Angiotensin  II  could  persist
despite treatment with ACE-I inhibitors since it can be formulated by non-ACE-I-depend‐
ent  pathways.  ARBs  can  also  block  the  angiotensin  II  receptor  without  an  increase  in
bradykinin levels [32].
Even with the utilization of ACE-I inhibitors or Angiotensin-Receptor blockers (ARBs) there
is not full suppression of Aldosterone synthesis. Aldosterone receptor blockers prevent sudden
cardiac death by controlling potassium loss, blocking aldosterone effect on the formation of
collagen and by increasing the myocardial uptake of norepinephrine, which decreases
sympathetic activation [32, 33]. Myocardial fibrosis may increase the risk of ventricular
arrhythmias by causing variations in the ventricular conduction times. Spirinolactone de‐
creases the level of serum markers of collagen synthesis at 6 months, which correlates with
survival benefit [33].
3.2. Effect of ACE-I on sudden cardiac death prevention in post myocardial infarction
patients and in patients with heart failure
Three post myocardial infarction trials; Survival and Ventricular Enlargement (SAVE),
Trandolapril Cardiac Evaluation (TRACE-I) and Acute Infarction Ramipril Efficacy (AIRE)
specifically investigated the impact of ACE-I inhibitors on mortality and morbidity in post MI
patients who have LV dysfunction.
Cardiomyopathies218
Survival and Ventricular Enlargement (SAVE) was a randomized double-blind placebo controlled
trial that evaluated the use of captopril (n=1115) versus placebo (n= 1116) in post MI patients
with LVEF ≤ 40%. Randomization was done 3-16 days post MI. During an average of 42 months,
there was an 18% RRR in all-cause mortality with captopril compared to placebo. However,
there was a non-significant trend towards lower SCD in patients taking captopril (odds ratio
0.83, 95% CI 0.63-1.8)[34].
Trandolapril Cardiac Evaluation (TRACE-I) was designed to examine whether patients with a
recent MI and LV dysfunction would benefit from long term ACE-I inhibitor therapy. A total
of 1749 patients 3-7 days post MI with echocardiographic evidence of LV dysfunction (EF≤
35%) were randomized to Trandolapril (n=876) or placebo (n=873). During follow up the
relative risk for death from any cause in the Trandolapril group versus the placebo group was
0.78 (95 percent confidence interval, 0.67 to 0.91). The Trandolapril group also showed a
significant reduction in sudden death versus the placebo group (HR 0.76, 95% CI 0.59-.98,
p=0.03) [35]. TRACE-I was the first placebo-controlled trial to show a significant reduction in
sudden death with the use of the ACE-I inhibitors.
The Acute Infarction Ramipril Efficacy (AIRE) Trial once again looked at the use of ACE-I
inhibitors in the post MI patient who had clinical or radiological evidence of congestive heart
failure (CHF) to receive Ramipril (n=1014) versus placebo (n=992). After 15 months of follow
up,there was a 27% reduction in the risk of death with Ramipril compared to placebo. In this
study Ramipril also reduced the risk for sudden death by approximately 30% compared to
placebo (p=0.011)[36].
A further Meta-analysis looked at 15 trials including SAVE, TRACE-I and AIRE to evaluate
the effect of ACE-I inhibitors on sudden death post MI. This meta-analysis revealed a signifi‐
cant reduction in the risk for sudden death an odds ratio of 0.80 (95% CI 0.70-0.92)[37].
Currently only three trials have reported results for sudden cardiac death in heart failure
patients taking ACE-I. The Cooperative North Scandinavian Enalapril Survival (CONSENSUS)
Study was designed to evaluate the effect of Enalapril compared to placebo on mortality in
patients with severe heart failure (class IV). This study randomized 253 patients to either
Enalapril (n=127) or placebo (n=126) in addition to conventional therapy. CONSENSUS
showed a 40% reduction in mortality after 6 months of treatment and a 27% reduction at the
end of the study. The greatest reduction in mortality was in death caused by progression of
pump failure[38].
The Studies of Left Ventricular Dysfunction (SOLVD)-Prevention trialwas designed to determine
whether and ACE-I inhibitor, Enalapril, could reduce mortality, the incidence of heart failure
and the rate of hospitalizations in patients with EF ≤ 35% with mild to moderate heart failure
(class II or III). Following randomization, patients received double-blind treatment with either
placebo (n=1284) or Enalapril (n=1285). There was noted a reduction in mortality due to
progression of heart failure with a risk reduction of 16% but no clear reduction in sudden
cardiac death was noted[39].
The V-HeFT-II trial was the first trial to suggest an effect of ACE-I inhibitors on sudden death
in patients with heart failure. This trial compared the effects of Enalapril with hydralazine and
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isosorbide dinitrate on mortality in patients with NYHA class II-III. After randomization,
double blind treatment was instituted with Enalapril (n= 403) versus hydralazine/isosorbide
dinitrate (n=401). Interestingly the mortality curves of the treatment arms separate early after
randomization. There was a 28% relative risk reduction with Enalapril compared to hydrala‐
zine and isosorbide dinitrate (p=0.16).The overall reduction in mortality associated with
Enalapril was due to a reduction in the incidence of sudden death [40].
3.3. Effect of Angiotensin-Receptor Blockers (ARBs) on sudden cardiac death prevention in
patients with congestive heart failure
The Evaluation of Losartan in the Elderly Study (ELITE) is the only ARB trial to demonstrate a
reduction in sudden death. This prospective, double-blind, randomized, parallel group
controlled clinical trial compared the safety and efficacy in the treatment of CHF with the use
of Losartan vs Captopril. Patients were randomly assigned to losartan (n=352) versus captopril
(n=370). Follow up at 48 weeks showed a 45% reduction in all-cause mortality with a relative
risk reduction of 36% in the incidence of sudden cardiac death [41].
ELITE II was designed to compare the effects of losartan and captopril on all-cause mortality
and sudden death or resuscitated cardiac arrest. Similar to ELITE patients were randomly
assigned to losartan (n=1578) or captopril (n=1574). After 1.5 years of follow there was no
statistically difference in all-cause mortality, sudden death or resuscitated cardiac arrest
(losartan 9% versus captopril 7.3%, p= 0.08) between the two groups[42].
3.4. Effect of Aldosterone antagonists on sudden cardiac death prevention in post MI
patients and in patients with congestive heart failure
The Randomized Aldactone Evaluation Study (RALES) was a randomized double-blind place‐
bo  controlled  trial.  This  trial  hypothesized  that  daily  treatment  with  Spirinolactone
would  reduce  the  risk  of  death  from  all  causes  among  patients  who  had  severe  heart
failure. Patients enrolled had class III or IV heart failure and were being treated with an
ACE-I inhibitor, loop diuretic and had an EF ≤ 35%. They were randomly assigned to ei‐
ther  Spirinolactone  (n=822)  or  placebo  (n=841).  This  trial  was  ended  prematurely  when
analysis  found that  Spirinolactone demonstrated a  31% reduction in cardiac  death.  This
reduction was due to a 36% in death related to progressive heart  failure and a 29% re‐
duction in sudden cardiac death [43].
The Eplerone Post Myocardial Heart Failure Efficacy and Survival Study (EPHESUS) was con‐
ducted to evaluate the effect  of  aldosterone blocker,  Eplerenone on morbidity and mor‐
tality  among  patients  with  acute  myocardial  infarction  complicated  by  left  ventricular
dysfunction  and  heart  failure.  In  this  double-blind,  placebo-controlled  study  patients
were  randomly assigned to  Eplerenone  (n=3313)  versus  placebo  (n=3319)  in  addition  to
optimal medical therapy. Eplerenone demonstrated a reduction in death from cardiovas‐
cular  causes  or  hospitalization  for  cardiovascular  events  (relative  risk,  0.83;  95%  CI,
0.72-0.94; p=0.005). There was also a reduction in sudden death from cardiac causes (rela‐
tive risk, 0.79; 95% CI 0.64-0.97; p=0.03) [44].
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4. Statins (3 hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors)
and sudden cardiac death prevention
4.1. Potential mechanisms of 3 hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
on sudden cardiac death prevention
Statins (3 Hydroxy-3-Methylglutaryl Coenzyme-A Reductase inhibitors) have been shown to
decrease cardiovascular morbidity and mortality in both primary and secondary prevention
trials. Statins are known to stabilize the plaque and to even promote plaque regression[45].This
stabilization improves myocardial perfusion, oxidative stress and reduces the risk of plaque
rupture[46]. This leads to decreased ischemic events and arrhythmic events, since even small
areas of ischemia can promote reentry, induce ventricular arrhythmias and lead to sudden
cardiac death. Statins improve endothelial function by increasing nitric oxide production from
endothelial cells and they reduce ischemia mediated oxidative stress and intracellular calcium
overload [47, 48]. They also have anti-inflammatory actions and reduce C-reactive protein, and
they decrease endothelin-1 secretion [49]. All these effects will decrease myocardial ischemia,
limit myocardial injury and prevent myocyte hypertrophy [50, 51].
4.2. Effect of statin therapy on shock burden and sudden cardiac death in post MI patients
and in patients with congestive heart failure
Statins are widely accepted as preventing coronary heart disease death and MI; however their
effect on sudden cardiac death prevention is unclear.
Randomized trial in post myocardial infarction patients showed the benefits of statins on
overall mortality but failed to show benefit on sudden cardiac death prevention [52-54].
However, observational data from hospitalized patients with myocardial infarction showed
that early statin administration (within 24 hours) of an acute MI led to a decrease in the
incidence of VT/VF [55].
Furthermore, statins appear to decrease appropriate shocks in patients who have ICDs whether
or not they received them for primary or secondary prevention of sudden cardiac death. In a
subanalysis of AVID trial, a secondary prevention trial which compared anti-arrhythmic drugs
to ICDs in patients who survived a cardiac arrest, patients who received statins had a lower
risk of ventricular arrhythmias compared to those who are not on statins [56]. This was also
demonstrated in the Multicenter Automatic Defibrillator Implantation Trial-II (MADIT-II).
Post hoc analysis of MADIT-II showed that patients receiving statin therapy > 90% of the time
had a significantly reduced cumulative rate of ICD therapy for VT/VF or cardiac death[57].
Subsequently, an analysis of SCD-HeFT trial data was undertaken to evaluate the impact of
statin use in heart failure. SCD-HeFT studied 2521 functional class II and III heart failure
patients with left ventricular ejection fractions ≤ 35%. The cause of CHF was ischemic in 52%
of the study patients. Statin use was reported in 965 (38%) of 2521 patients at baseline and 1187
(47%) at last follow-up with the median time to follow up of 45.5 months. This analysis revealed
that mortality reduction related to statin therapy (HR= 0.70, 95% CI: 0.58-0.83] was identical
in both ischemic and non-ischemic cardiomyopathy (HR 0.69 vs 0.67 respectively) [58].
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5. Conclusions and future directions
Sudden cardiac death remains a challenge for health providers and policy makers. Whether
more stringent guidelines for prevention and screening will be applied is balanced by the
enormous costs. In order to identify the groups at risk for sudden cardiac death there must
first be a standardization of the definition. The worldly variation in this definition of sudden
cardiac death of 1 hour from onset of symptoms to 24 hours, not only effects epidemiological
data but also alters clinical trial outcomes when evaluating the effectiveness of treatment
options.
Currently, antiarrhythmic medications have failed to show any benefit of sudden cardiac death
prevention, while traditional heart failure medications have been shown to decrease total
mortality, sudden cardiac death and defibrillator shocks. They are only used in a small subset
of patients that present in sudden cardiac death, since most of the patients who have sudden
cardiac death have it as a first presentation and do not have congestive heart failure or history
of coronary artery disease. This poses a diagnostic and therapeutic challenge for the clinician.
Taking statins as an example, most of the primary prevention algorithms used to start lipid
lowering agents usually leads to delayed intervention, especially since coronary atheroscle‐
rosis has been shown to start at a young age. The cost of starting this treatment is also enormous,
especially if it is started on a global scale at a young age and it is not without side effects.
Genetic studies to identify patients at risk for coronary atherosclerosis are still under devel‐
opment. Preventing sudden cardiac death is definitely a challenge for the 21st century clinician
and might remain so for the near future.
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